Controlled Low Calorie Diet in Reducing Side Effects and Increasing Response to Chemotherapy in Patients With Breast or Prostate Cancer



Status:Recruiting
Conditions:Breast Cancer, Prostate Cancer, Cancer, Cancer, Cancer
Therapuetic Areas:Oncology
Healthy:No
Age Range:19 - Any
Updated:4/17/2018
Start Date:January 29, 2013
End Date:January 29, 2020
Contact:Cheryl Kefauver, RN
Email:Cheryl.Kefauver@med.usc.edu
Phone:323-865-0459

Use our guide to learn which trials are right for you!

A Randomized, Phase II Clinical Trial of a Controlled Diet Prior to Selected Chemotherapy Treatment in Breast and Prostate Cancer to Evaluate the Impact on Toxicity and Efficacy

This randomized phase II trial studies how well a controlled low calorie diet works in
reducing side effects and increasing response to chemotherapy in patients with breast or
prostate cancer. Drugs used in chemotherapy work in different ways to stop the growth of
cancer cells, either by killing the cells or by stopping them from dividing. Eating a special
diet with low calories may reduce the side effects of chemotherapy and improve the response
to treatment

PRIMARY OBJECTIVES:

I. To obtain preliminary estimates of the impact of a restricted diet on toxicity and
efficacy of chemotherapy for breast and prostate cancer.

II. To evaluate the compliance with a controlled diet intervention.

III. To investigate changes in plasma insulin, glucose, insulin-like growth factor 1 (IGF1)
and IGF binding protein (IGFBP) levels in subjects who consume a restricted diet compared to
controls.

OUTLINE:

Patients are randomized to 1 or 2 treatment arms.

ARM I: Patients eat a special low-calorie diet during 3 days prior to chemotherapy, during
the 12 weeks of chemotherapy, and 24 hours after chemotherapy. Patients are provided with all
meals and all food to be consumed and maintain a diary of the food consumed and appropriate
amounts. Patients meet with the study dietician within 3 weeks of enrollment and prior to, or
on the day of, their first course of chemotherapy on study and at the start of each
subsequent course.

ARM II: Patients eat a normal diet and receive dietary advice which may include consultation
with a nutritionist. Patients maintain a diary of the food consumed and appropriate amounts.

Inclusion Criteria:

- Histologically confirmed breast cancer for which chemotherapy with AC (doxorubicin
plus cyclophosphamide) is being utilized in the neoadjuvant or adjuvant setting OR
metastatic prostate adenocarcinoma for which Docetaxel will be administered

- Body mass index (BMI) >= 18.5

- Subjects do not need to have measurable or evaluable disease; chemotherapy may be
administered in the neoadjuvant, adjuvant, or metastatic setting

- Prior therapy:

- Breast cancer subjects may not have received prior chemotherapy, with the
exception of curative-intent chemotherapy for a separate malignancy more than 3
years ago

- Prostate cancer subjects may have received prior treatment with metronomic
cyclophosphamide as this is considered anti-angiogenic/immunomodulatory and not
cytotoxic

- Prostate cancer subjects may be receiving a 2nd course of docetaxel provided that
** The first course resulted in a PSA response (> 30% reduction in prostate
specific antigen [PSA] and/or improvement in radiographic findings or pain) and
the last dose was >= 9 months ago

- Prior Radiotherapy is allowed, provided at least 2 weeks have elapsed from completion
of radiotherapy to initiation of protocol treatment

- Eastern Cooperative Oncology Group (ECOG) performance status 0-1

- Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) < 2x upper limit
of normal (ULN)

- Absolute neutrophil count (ANC) > 1500

- Platelets (plts) > 90,000

- Premenopausal women must have a negative pregnancy test and must agree to use barrier
contraception throughout the study period

Exclusion Criteria:

- Diabetes Mellitus

- Peripheral Neuropathy >= grade 1

- Prior therapy with inhibitors of IGF-1

- Concurrent use of somatostatin

- Significant food allergies which would make the subject unable to consume the food
provided (ex: shellfish, soy or egg allergy)
We found this trial at
3
sites
1441 Eastlake Ave
Los Angeles, California 90033
(323) 865-3000
Principal Investigator: David I. Quinn, MD
Phone: 323-409-4363
U.S.C./Norris Comprehensive Cancer Center The USC Norris Comprehensive Cancer Center, located in Los Angeles, is...
?
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Newport Beach, California 92663
Principal Investigator: Diana Hanna, MD
?
mi
from
Newport Beach, CA
Click here to add this to my saved trials
200 First Street SW
Rochester, Minnesota 55905
507-284-2511
Phone: 507-538-7623
Mayo Clinic Rochester Mayo Clinic is a nonprofit worldwide leader in medical care, research and...
?
mi
from
Rochester, MN
Click here to add this to my saved trials